They already have the safety data,it was the primary endpoint of the study,and it was good. They`re waiting on the secondary endpoint data,which was efficacy,and they should be getting it in a few months.
The near term event that will impact the longer term future of HER2 is PETX gaining USDA approval to commercialize the construct for veterinary application. I know we're talking dogs vs human applications but the similarities and parallels of the target cancers are very strong.
The required PETX field trials of AT-014 were good or PETX could not or would not have proceeded with the USDA conditional approval request.
I believe researchers are well aware of the human applications for HER2 and the broader implications if it's successful treating canine osteosarcoma.
News 
Market Data 
Discover 
